Subscribe to RSS Feed

New Blood Test Could Provide More Precise Prostate Cancer Risk Assessment

NEW YORK, NY--(Marketwired - Mar 25, 2014) - A new prostate cancer blood test, currently in testing, may
 soon facilitate more precise prostate cancer diagnosis. Early findings indicate that gene mutations, similar to those identified in breast cancer screenings, may help experts more accurately predict a man's risk of aggressive prostate cancer. More widespread availability of the prostate cancer genetic screener is anticipated within the next year.

Prostate cancer is currently diagnosed through a combination of assessments, including routine prostate-
specific antigen (PSA) blood tests, a digital rectal exam (DRE), and a prostate biopsy. "While the PSA test is very valuable, it is not a prostate cancer specific test," explains David B. Samadi, MD, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital. "Elevated PSA levels can indicate an enlarged prostate, prostate inflammation, or prostate cancer."

In vetting this new diagnostic tool, researchers are
exploring how second-generation sequencing technology can be used to determine the frequency of mutations in 22 tumor suppressor genes and how those mutations correlate to prostate cancer risk and disease aggression. In an initial study, 191 men with strong family histories of prostate cancer were tested for the 22 tumor suppressor genes. Among the study participants, researchers identified 14 loss-of-function (LoF) mutations commonly associated with aggressive or advanced-stage prostate cancers.

Understanding how the frequency of mutations may predispose men to familial and/or aggressive prostate cancer may change the course of care. "In-depth assessment of an individual's genetic predispositions opens the door to tailored prostate cancer screening; individualized attention is always our goal," said Dr. Samadi.

Prostate cancer genetic testing could mean a more customized approach to prostate cancer prevention, screening, and treatment. The combination of known risk factors and genetic predispositions would allow men to make adjustments in diet and lifestyle, and give medical professionals the opportunity to screen in a very targeted way.

"My hope is that in the near future men who are diagnosed with prostate cancer can leverage genetic knowledge to make treatment decisions based on their individual disease aggression and recurrence risk," stated Dr. Samadi. "For example, if a man carries these genetic mutations we may preemptively start radiation after robotic prostate surgery to further reduce the risk of recurrence."

The study findings were published on February 20, 2014, in the British Journal of Cancer, 

Back to Press Releases

Bookmark Using:
Facebook Twitter LinkedIn Email Yahoo

Share on Facebook

Call to Make an Appointment With Dr. David Samadi:


Click the contact link to learn how Dr. Samadi can help treat your prostate cancer and give you back your quality of life.

* The benefits of robotic surgery cannot be guaranteed as surgery is both patient and procedure specific. Previous surgical results do not guarantee future outcomes.

Steve S. New Jersey, USA

Dr. Samadi is a unique person having reached the pinnacle of his profession, while at the same time treating all his patients with compassion as though they are members of his immediate family.

Mr. Smith, USA

ODE TO DR. DAVID SAMADI *Dr. Samadi :  How can I find the words  to thank you for saving my life?   There are no words! *Dr. Samadi:  How can I thank you for your masterful...

Dr. Theodore Lazzaro, USA

As medical director of Aestique® Medical Center & Spa, Dr. Theodore A. Lazzaro’s main goal is simple: to improve the quality of life for his patients. And now as a prostate cancer survivor, he shares these goals with the surgeon who saved his life.

T. C., Oslo, Norway

"I was lucky to find Dr. David Samadi: a patient, caring, gifted healer who surpassed all my expectations. He has earned my deepest respect and gratitude, and I recommend him unconditionally..."